Clinical Trials Logo

Clinical Trial Summary

The overall purpose of the study was to describe the real-life adherence, effectiveness and safety of the Kaletra Adherence Support Assistance (KASA) Program in human immunodeficiency virus (HIV)-positive patients who were receiving treatment with lopinavir / ritonavir (LPV/r; Kaletra®) in Canada.


Clinical Trial Description

The Kaletra Adherence Support Assistance (KASA) Program is a customized support network that has been offered to patients treated with lopinavir / ritonavir (LPV/r; Kaletra®). KASA offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events. Patients enrolled in KASA may also have access to various healthcare professionals (dietician, social worker, psychologist, etc.) or may be offered other types of support (transportation, exercise, etc.), which may help improve their quality of life as well as adherence or compliance while taking LPV/r.

This was a 12-month, multi-center, Canadian Post Marketing Observational Study utilizing a prospective single cohort design. All treatments including participation in the KASA program were according to the decision of the treating physician and the patients and were not affected in any way by their decision to participate in the study. Follow-up was for 12 months at an interval of every six months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01662336
Study type Observational
Source AbbVie
Contact
Status Completed
Phase N/A
Start date June 2012
Completion date June 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05981807 - HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
Completed NCT01490359 - Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men N/A
Completed NCT03143205 - Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men N/A
Completed NCT02738138 - A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) Phase 3
Completed NCT01791465 - Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults Phase 4
Completed NCT01869634 - Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Phase 4
Completed NCT01383005 - Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) N/A
Completed NCT01328158 - Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection N/A
Completed NCT00711009 - Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) Phase 3
Completed NCT02817451 - DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants Phase 3
Completed NCT02214173 - The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV N/A
Completed NCT03284645 - Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
Terminated NCT01737359 - A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. Phase 2
Active, not recruiting NCT05141422 - A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers Phase 1
Completed NCT01939197 - A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection Phase 2/Phase 3
Completed NCT01447680 - Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing N/A
Not yet recruiting NCT05769413 - Awareness of Osteoporosis in HIV Patients
Withdrawn NCT01738555 - A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects Phase 2